All the news Showing 10 of 12 articles from: Genotype 4Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) Manual Items / 26 July 2016 Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes Manual Items / 02 November 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 FDA approves Technivie for treatment of chronic hepatitis C genotype 4 FDA / 27 July 2015 NICE consults on draft guidance recommending ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C NICE / 04 March 2015 OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection Reuters / 16 May 2014 European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead press release / 17 January 2014 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive